TCGA-CR-5250-01A-01R-1514-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.380
- APICAL_SURFACE+0.340
- MITOTIC_SPINDLE+0.280
- WNT_BETA_CATENIN_SIGNALING+0.270
- UV_RESPONSE_DN+0.210
- HEDGEHOG_SIGNALING+0.180
- TGF_BETA_SIGNALING+0.170
- G2M_CHECKPOINT+0.150
- E2F_TARGETS+0.130
- IL6_JAK_STAT3_SIGNALING+0.120
Top 10 suppressed
- MYC_TARGETS_V1-0.500
- MYC_TARGETS_V2-0.490
- INTERFERON_ALPHA_RESPONSE-0.480
- MTORC1_SIGNALING-0.480
- OXIDATIVE_PHOSPHORYLATION-0.450
- CHOLESTEROL_HOMEOSTASIS-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.390
- INTERFERON_GAMMA_RESPONSE-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- PROTEIN_SECRETION-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-5153-01A-01R-1436-07 | — | — | 0.823 |
| 2 | TCGA-AC-A3QQ-01B-06R-A22O-07 | — | D | 0.811 |
| 3 | TCGA-CR-5243-01A-01R-1514-07 | — | — | 0.781 |
| 4 | TCGA-F7-7848-01A-11R-2132-07 | — | — | 0.775 |
| 5 | TCGA-58-8388-01A-11R-2326-07 | — | cohortSQ1 | 0.739 |
| 6 | SRR13311176 | — | — | 0.738 |
| 7 | TCGA-56-A5DS-01A-11R-A27Q-07 | — | cohortSQ1 | 0.735 |
| 8 | SRR6013530 | — | cohortSQ1 | 0.733 |
| 9 | 4b4a3828-d808-4d25-a06c-b738fd8daacb | — | — | 0.733 |
| 10 | TCGA-CV-6939-01A-11R-1915-07 | — | — | 0.730 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.340 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.050 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.020 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |